UC San Diego Health, the region’s only academic medical center, delivers world-class care and translates groundbreaking research into promising new treatments for patients.
In an effort to help schools reduce the risk of COVID-19 outbreaks as they resume in-person instruction, UC San Diego and the County of San Diego are testing the Safer at School Early Alert system to detect SARS-CoV-2 at schools and child care centers.
Researchers identify molecular mechanism for the anti-inflammatory activity of diabetes drug metformin and, in mouse studies, say it prevents lung inflammation in animals infected with SARS-CoV-2, the virus that causes COVID-19.
UC San Diego researchers report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer’s disease.
UC San Diego researchers report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Using anonymized medical records from a national registry, UC San Diego researchers confirm earlier findings that statins may substantially minimize adverse outcomes from SARS-CoV-2 infection.
Mining a large database of adverse reactions to medications, UC San Diego researchers found that people who took proton pump inhibitors (e.g., Prilosec, Nexium) for heartburn and acid reflux were more likely to experience kidney disease than people who took other forms of antacid.
San Diego Magazine, October 29
Imperial Valley Weekly, November 2
FOX 5, November 5
Escondido Times-Advocate, November 5
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
